Vitaz — Clinical Trial Site

117 Registered trials

48 Currently recruiting

Organisation

Vitaz

Location

Sint-Niklaas, Belgium

Identifier

ORG-100041146

Address

Moerlandstraat 1, 9100, Belgium

Departments

#1002: medical oncology
032008: Medische Oncologie
056011: Medische Oncologie
4202 : Pneumology
BE10002:Gastro-enterologie
BE10005: Gastro-entérologie
Cardiology
Departement of Hematology
Department of Oncology
Department of Urology
Diabetology-Endocrinology
Dienst longziekten
Division of Pulmonary and Infectious Diseases
Endocrinology
Gastro Enterology
Gastro-enterologie
Gastro-enterology
Gastroenterology
Gastroenterology - Hepatology
Gastrogroep
Haematology
Hematologie
Hematology
Internal diseases
Longziekten
Medical Oncology
Medical Oncology/Hematology
Medische oncologie
n/a
NA
Neurology
Nierziekten & Dialyse
Oncologie
Oncology
Palliative care
Pneumologie
pneumology
Psychiatry
Pulmonary
Pulmonary and Infectious Disease
Pulmonary and Infectious Diseases
Pulmonary diseases department
Pulmonology
Thoracic oncology
Urology

Clinical trials at this site (117)

Search interface

Clinical trial of MK-7648A in adults and children with skin cancer Not authorised

2022-501417-31-00 High-risk Resected Melanoma 5
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inh… Not authorised

2023-505311-20-00 Metastatic Non-Small Cell Lung Cancer 5
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending

2024-519298-21-00 Cancer-Associated Thrombosis (CAT). 5
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R… Pending

2024-519818-31-01 Endometrial Cancer Advanced, Recurrent, Metastatic, or 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Pending

2025-521038-27-00 Immune system diseases 5
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after… Pending

2025-521908-22-00 EGFR-mutated Non-small Cell Lung Cancer 10
Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiot… Pending

2025-523575-36-00 Locally advanced head and neck squamous cell carcinoma 4
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5
The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting

2024-518589-29-00 Bronchiectasis 5 2025-08-21
A phase III study on using immunotherapy and radiotherapy to treat limited spread of Head and Neck Cancer Recruiting

2023-504478-39-00 Squamous cell carcinoma of head and neck 5 2025-05-23
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c… Recruiting

2023-505606-42-00 Head and Neck Squamous Cell Carcinoma (HNSCC) 5 2024-10-15
Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting

2023-508304-38-00 Ulcerative Colitis (UC) 4 2024-09-10
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant… Recruiting

2023-505678-14-00 Ulcerative Colitis 4 2024-08-19
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial Recruiting

2022-501551-90-00 Prostate cancer 10 2023-12-13
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit… Recruiting

2024-520101-39-00 TROP2 NMR-positive advanced or metastatic non-squamous 5 2026-04-01
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting

2025-522674-36-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2026-03-24
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02